Search
Search

OncoPro Tumoroid Cell Lines |
Kick-off your 3D cancer research workflow with our Gibco OncoPro Tumoroid Cell Lines. Also referred to as cancer organoid cell lines, these models are established from primary patient tissues and have been fully characterized. Thermo Fisher Scientific and Discovery Life Science (Discovery) have partnered to broaden the availability of high-quality, culture-ready, patient-specific tumoroid cell lines and services across a wider range of cancer indications. Discovery will now offer tumoroid cell lines that have been derived and expanded in Gibco OncoPro Tumoroid Culture Medium. This medium has been specifically formulated to support the optimal growth of tumoroid cell lines.
When cultured in OncoPro Tumoroid Culture Medium, OncoPro Tumoroid Cell Lines help support quality 3D cancer research since these lines are:
| Tumoroid line | Diagnosis - Stage | Tumor site | Race Sex, Age | Height (in), Weight (lb) | Treatment status |
|---|---|---|---|---|---|
| HuCo031721 | Colorectal adenocarcinoma - IIA | Transverse colon | White Male, 82 | 70", 260 lb | Pre-Treatment |
| HuCo111622 | Colorectal adenocarcinoma - IIA | Rectum | White Female, 70 | 63", 215 lb | Pre-Treatment |
| HuCo083123 | Colorectal adenocarcinoma - IIIC | Rectosigmoid | White Male, 46 | 70", 248 lb | Pre-Treatment |
| HuCo090123 | Poorly differentiated adenocarcinoma - IIA | Colon | African-American Female, 90 | 63", 138 lb | Pre-Treatment |
| HuCo100523 | Colorectal adenocarcinoma - IIA | Ascending colon | White Female, 85 | 62", 148 lb | Pre-Treatment |
| HuCo052121 | Colorectal adenocarcinoma - IIA | Rectum | White Female, 46 | 60", 154 lb | Pre-Treatment |
| HuCo1044 | Colorectal adenocarcinoma - IIIB | Transverse colon | White Female, 80 | 61", 343 lb | Pre-Treatment |
| HuCo3209 | Colorectal adenocarcinoma - I | Sigmoid colon | White Female, 59 | 67", 176 lb | Pre-Treatment |
| HuCo021320 | Colorectal adenocarcinoma - IVC | Colon | White Female, 58 | 65", 176 lb | Pre-Treatment |
| HuLu051421* | NSCLC, Squamous cell carcinoma - IA3 | Middle lobe of lung | White Male, 63 | 75", 209 lb | Pre-Treatment |
| HuLu051921* | NSCLC, Large cell carcinoma - IIA | Upper lobe of lung | White Female, 69 | 67", 169 lb | Pre-Treatment |
| HuBr102622* | Invasive ductal carcinoma, ductal carcinoma in situ present - IA | Breast | White Female, 56 | 63", 131 lb | Pre-Treatment |
| HuEn061022 | Endometrioid carcinoma - IA | Endometrium | White Female, 67 | 65", 162 lb | Pre-Treatment |
| HuEn070722* | Dedifferentiated carcinoma - IIIC1 | Endometrium, lower uterine segment | White Female, 76 | 66", 272 lb | Pre-Treatment |
| HuEn041521* | Endometrioid carcinoma - IIIC1 | Endometrium | White Female, 78 | 60", 189 lb | Pre-Treatment |
| HuEn022222 | Endometrioid carcinoma - IA | Endometrium | White Female, 58 | 62", 150 lb | Pre-Treatment |
| HuEn033122 | Endometrioid carcinoma - IA | Endometrium | White Female, 59 | 64", 200 lb | Pre-Treatment |
*Now available directly through Discovery Life Sciences.
Explore relevant data that demonstrate the quality and consistency of OncoPro Tumoroid Cell Lines. In-depth characterization data is available for each tumoroid cell line upon request by completing an inquiry form.
Figure 1. Tumoroid cell lines preserve donor-specific mutations. Unique genomic mutations are preserved between primary tumors and established tumoroid cultures. Next-generation sequencing (Oncomine Comprehensive Assay v3) was used to identify single-base substitutions (bar graphs), oncogenic mutations, and copy number variations (heat map).
Figure 2. OncoPro Tumoroid Cell Lines maintain major characteristics during long-term culture in OncoPro Tumoroid Culture Medium. (A) Cumulative population doubling (PD) was measured by cell counts at each passage. Tumoroid lines were recovered from cryopreservation at the beginning of this experiment (day 0), and additional cryopreservation and recovery points are indicated by arrows for each culture. (B) Representative images of tumoroid morphology before and after prolonged culture. (C) Correlation of germline and somatic single nucleotide variations (SNVs) between early and later passage tumoroid cultures. Each dot represents the variant allelic frequency (VAF) for one genetic locus covered by the Oncomine Comprehensive Assay v3. (D) Principal component analysis of tumoroid transcriptomes demonstrates that tumoroids cluster by donor rather than by passage. (E) Differential gene expression analysis of early versus late passage tumoroids reveals a modest number of differentially expressed genes (DEGs) at fold change >2 and false discovery rate (FDR) <0.05. Gene ontology analysis revealed a few significantly enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways (FDR <0.05) between early and late passage tumoroid cultures; the top 10 results are shown.
Figure 3. Tumoroid lines grow consistently in an easy-to-use, scalable format.(A) Expansion rates of tumoroids in suspension culture in OncoPro medium. Number of cells counted after thawing from cryopreservation (day 0) and at each passage. (B) Individual samples have consistent growth rates and can typically generate 100 million viable cells within 30 or 60 days.
Long-term maintenance of patient-specific characteristics in tumoroids from six cancer indications
The serum-free Gibco OncoPro Tumoroid Culture Medium enables establishment and maintenance of tumoroid lines from multiple cancer indications, retaining key tumor characteristics and supporting applications in cancer research, drug discovery, and personalized medicine.
Cancer organoids are known to have complex culture requirements that can be challenging. The OncoPro Tumoroid Culture Medium Kit helps simplify tumoroid culture with well-defined, easy-to-follow protocols, helping make physiologically relevant cancer models more accessible.
Co-culturing patient-derived cancer organoids with fibroblasts and endothelial cells
Cancer organoids vs cancer spheroids
How 3D cell culture models work
Cancer organoids in CAR T cell therapy research
Effective techniques for cancer organoid culture
Advancing cancer cell-based assays with assay-ready tumoroids
Thermo Fisher Scientific Partners with AIM Biotech on Development of Microphysiological Systems
Scaling Human-Relevant Oncology Testing: OncoPro Tumoroids on ScreenIn3D’s UpScale Platform
Visit our tumoroid webpage to learn about these models and how they can be utilized in cancer research.
Discover an off-the-shelf tumoroid culture medium that simplifies tumoroid culture.
Learn the fundamentals of 3D cell culture, including differences between cell models, cell types, and 2D vs. 3D systems.
仅供科研使用,不可用于诊断目的。
